India
Review Article
Systemic Review on Chronic Myeloid Leukemia: Therapeutic Targets, Pathways and Inhibitors
Author(s): Himansu Kumar, Utkarsh Raj, Saurabh Gupta, Rashmi Tripathi and Pritish Kumar VaradwajHimansu Kumar, Utkarsh Raj, Saurabh Gupta, Rashmi Tripathi and Pritish Kumar Varadwaj
Chronic Myeloid Leukemia (CML) is a stem cell disorder, characterized by the translocation of 9th chromosome of Abelson (ABL) gene to the 22th chromosome of breakpoint cluster region (BCR) gene. Consequently, translocation results into the chimeric oncogene BCR-ABL which encodes the BCR-ABL oncoprotein. CML is mainly a disease of adults but it can occur in any stage of life and it accounts around 15% of the all the types of leukemia. Various methods have been used to combat this disease like Chemotherapy, Radiation therapy; tyrosine kinase inhibitors etc., Imatinib as a tyrosine kinase inhibitor has dramatically improved the survival rate of CML patients, hence can be referred as first generation drug against the CML. Later on, recurrence of the disease in some treated patients has also been seen probably due to mutation in oncogenes. Researchers have started to find out more efficien.. Read More»
DOI:
10.4172/2155-9619.1000257
Nuclear Medicine & Radiation Therapy received 706 citations as per Google Scholar report